April 24, 2024
Source: Press Release, Prague, Basel and Boston
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024, in Chicago, IL.
BOXR1030 is a next-generation GPC3-targeted CAR T-cell therapy enhanced with a transgene encoding GOT2, a critical enzyme involved in cellular metabolism. Preclinical studies of BOXR1030 have demonstrated its superior activity compared to standard CAR T-cell therapies. It is the most advanced therapeutic candidate from SOTIO’s BOXR platform of enhanced cell therapies for the treatment of solid tumors.
The DUET-01 clinical trial is a first-in-human, open-label, multicenter, dose escalation study to assess and determine the recommended Phase 2 dose of BOXR1030 in patients with GPC3 positive advanced solid tumors. The trial will enroll up to 98 patients with advanced, unresectable hepatocellular carcinoma, squamous cell lung cancer, myxoid/round cell liposarcoma, and Merkel cell carcinoma.
Poster details are as follows:
Title: “DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors”
Abstract Number: TPS2681
Session: Developmental Therapeutics — Immunotherapy
Date & Time: June 1, 2024, 9:00 a.m. – 12:00 p.m. CDT
Presentation materials will be available after presentations conclude here.
